- Home
- CPBI vs IMA Comparison
CPBI vs IMA Comparison
Compare CPBI & IMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CPBI | IMA |
|---|---|---|
| Founded | 2023 | 2019 |
| Country | United States | United States |
| Employees | N/A | 15 |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 74.5M | 54.8M |
| IPO Year | 2023 | N/A |
Fundamental Metrics
Financial Performance| Metric | CPBI | IMA |
|---|---|---|
| Price | $17.75 | $5.78 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $16.00 |
| AVG Volume (30 Days) | 3.8K | ★ 371.8K |
| Earning Date | 06-12-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.80 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $21.93 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.52 | $3.94 |
| 52 Week High | $17.89 | $17.50 |
Technical Indicators
Market Signals| Indicator | CPBI | IMA |
|---|---|---|
| Relative Strength Index (RSI) | 56.20 | 52.91 |
| Support Level | $16.88 | $3.94 |
| Resistance Level | $17.88 | $7.28 |
| Average True Range (ATR) | 0.27 | 0.53 |
| MACD | 0.05 | 0.14 |
| Stochastic Oscillator | 87.67 | 64.07 |
Price Performance
Historical ComparisonAbout CPBI Central Plains Bancshares Inc.
Central Plains Bancshares Inc operates as the bank holding company for Home Federal Savings and Loan Association of Grand Island that provides mortgage, consumer, commercial real estate, and commercial loans, The bank business consists mainly of accepting deposits from the general public and investing those deposits, together with funds generated from operations, in one- to four-family residential mortgage loans secured by properties located in primary market area, as well as commercial real estate loans.
About IMA ImageneBio Inc.
ImageneBio Inc is a clinical-stage biopharmaceutical company developing therapeutics for patients with immunological, autoimmune and inflammatory diseases. The company's flagship asset, IMG-007, is a non-depleting anti-OX40 monoclonal antibody that binds specifically to OX40 receptor on activated T cells to block receptor binding to OX40 ligand (OX40L). IMG-007 is being developed to potentially treat multiple autoimmune and inflammatory diseases and disorders. The company operates in a single segment.